Member Info for Mars1

As Michael Reynolds the founder of Ebers Tech is at Merrill I thought this article might be of interest as in the original Ebers RNS it was noted that they were connected to a vertically integrated US cannabinoid co. The article covers listed US companies selling in Canada with Merrill providing price forecasts.
https://www.msn.com/en-us/money/companies/merrill-lynch-is-very-high-on-5-top-buy-rated-marijuana-stocks/ar-AAE1lHE

Asia also includes India loads of scope

This is the quote from the recent RNS “ notes the recent share price movement and press reports. It confirms that the Company is in discussion with multiple potential licensees in Japan and Asia, including but not limited to its NXP002 programme.”
Note it is Asia and Japan may not be limited to just China, could mean South Korea or...

From the additional patent filing in Sept 2018 which probably indicates a further benefit was discovered.
“ Fibrotic disease is typically associated with high patient mortality, increasing prevalence and a lack of safe and effective treatments. Whilst, fibrosis treatments are in their infancy the emerging lung fibrosis market demonstrates their blockbuster potential. Markets for other fibrotic conditions are under-developed, with large and growing patient populations (e.g. the global liver disease market is predicted to reach $12.1 billion by 2022).

Using cutting-edge human tissue disease models, Nuformix has previously demonstrated the potential for NXP002 to attenuate progression in established lung and liver fibrosis. This additional patent filing provides further strength and breadth to the existing NXP002 patent portfolio to best support further development and commercialisation for its NXP002 programme.”

ILD is lung fibrosis is this the team carrying out the human trials https://royalpapworth.nhs.uk/our-services/respiratory-services/ild/meet-team

ABGs explained https://nurse.org/articles/arterial-blood-gas-test/

https://mobile.twitter.com/mut75/status/1186217389299507200/photo/1

Tweet from Muhunthan Thillai “The new edition of our lung function book is out in all good shops now! With an excellent forward by Dr. Karl Sylvester!
@CambsRespPhys

@RoyalPapworth

@RoyalPapRes

@PSJBailey
Image

Newspapers tend not to like being used. Journalist would have had to validate source before editorial approval despite what we think about news items they do try most of the time

This is not just commercial this has significant benefit to those suffering lung fibrosis

Results of the pre clinical trial Dec 18;
Multi-patient tissue studies were performed in partnership with Newcastle University, UK using a leading-edge human tissue trial model that closely replicates the clinical disease:



· Data demonstrates NXP002 candidates strongly inhibit fibrosis ex-vivo, even in very severely fibrotic patient tissue, giving strong support for treating IPF and other fibrotic lung conditions

· In addition, NXP002 demonstrated specific action measured against key inflammatory targets

· NXP002 out-performed current standard of care treatment, Esbriet ® (pirfenidone)

Attracting the lead consultant in the country says it all for NXP002

In the podcast he said they will have a better idea of NXP002 timeline and should have more news on commercial discussions. Well with another listen did so last week.

Last podcast 6/9 when discussing the appointment of Muhunthan Thillai

Beauty about the incoming contracts are they are all revenue little or no extra cost. The Kissei reference by the Times is interesting because the terms mentioned are not too dissimilar to terms with ano pharma last year kerching

As a shirt sponsor are they restricted to what can go on the shirt. If for example the SDK is live will the Bids logo change to ANO advert #wheninthegame?

Just caught up with the EA news and had a quick look at Twitter. Umbro Ireland retweeted the following message “ The kit will be available in-game from Friday & is coming soon to http://Umbro.ie. ??” wondered which kit they were referring to SDK or shirts?

NFX?

Does not take much to move the price mms desperate for stock towards the end very tight book the seller relieved the pressure whoever needs to apply more subtlety to their selling

Lootgaloot good luck mate, take a deep breath there is now a precedent for defamation on the internet nothing easier especially when it is in writing can be very costly. Nothing like taking a period out of of context shows a pretty clear lack of understanding of the advertising industry boom